The COMPLETE (MA.31) study compared HER2 directed therapy with lapatinib vs trastuzumab plus paclitaxel for 24 weeks followed by the same HER2 directed agent until disease progression in women with HER2 + metastatic BC. Here, ERBB2 is linked to breast cancer.